
# Title 42 - Public Health
## Chapter IV - Centers for Medicare & Medicaid Services, Department of Health and Human Services
### Subchapter B - Medicare Program
#### PART 412 - PROSPECTIVE PAYMENT SYSTEMS FOR INPATIENT HOSPITAL SERVICES
##### Subpart F - Payments for Outlier Cases, Special Treatment Payment for New Technology, and Payment Adjustment for Certain Replaced Devices
###### Additional Special Payment for Certain New Technology
####### ยง 412.87 Additional payment for new medical services and technologies: General provisions.
######## Eligibility criteria for alternative pathway for certain antimicrobial products.

(d)(1)(i) A new medical product is designated by FDA as a Qualified Infectious Disease Product and has received marketing authorization for the indication covered by the Qualified Infectious Disease Product designation; or

(ii) For discharges occurring on or after October 1, 2021, a new medical product is approved under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) and used for the indication approved under the LPAD pathway.

(2) A medical product that meets the condition in paragraph (d)(1) of this section will be considered new for not less than 2 years and not more than 3 years after the point at which data begin to become available reflecting the inpatient hospital code (as defined in section 1886(d)(5)(K)(iii) of the Social Security Act) assigned to the new technology (depending on when a new code is assigned and data on the new technology become available for DRG recalibration). After CMS has recalibrated the DRGs, based on available data, to reflect the costs of an otherwise new medical technology, the medical technology will no longer be considered "new" under the criterion of this section.

(3) The new medical product meets the conditions described in paragraph (b)(3) of this section.
